IPSEN BIOPHARMACEUTICALS, INC. is the U.S. subsidiary of Ipsen S.A., a global biopharmaceutical company headquartered in Paris, France, founded in 1929 by Henri Beaufour. While Ipsen S.A. is publicly traded on Euronext Paris (IPN), the Beaufour family maintains significant control, holding 57% of shares and 73% of voting rights as of 2024-2025. Ipsen S.A. employs approximately 5,000 to 5,700 individuals worldwide, with 5,358 employees in 2024, and reported revenue of €3.401 billion in 2024. The North American headquarters for Ipsen is located in Cambridge, Massachusetts.
Ipsen focuses on the research, development, and commercialization of transformative medicines across three core therapeutic areas: oncology, rare diseases, and neuroscience. Key product lines include Somatuline® (lanreotide), Onivyde® (irinotecan liposome injection), and Cabometyx® (cabozantinib) for oncology; Sohonos® (palovarotene) and Iqirvo® (elafibranor) for rare diseases; and Dysport® (abobotulinumtoxinA) for neuroscience. The company divested its Consumer HealthCare division in 2022 to concentrate on its specialty care portfolio.
In terms of patent litigation, IPSEN BIOPHARMACEUTICALS, INC. exhibits the posture of an operating company actively protecting its intellectual property. The company has appeared as a plaintiff in one tracked case and has no recorded appearances as a defendant. This indicates that it asserts its own patents rather than primarily defending against infringement claims. The sole tracked case is in the U.S. District Court for the District of New Jersey, a common venue for pharmaceutical patent disputes, and not typically associated with non-practicing entity (NPE) assertions.
The company's only tracked case, IPSEN BIOPHARMACEUTICALS, INC. et al. v. CONJUPRO BIOTHERAPEUTICS, INC. et al., commenced on April 15, 2024. This litigation aligns with Ipsen's business as a biopharmaceutical developer, suggesting efforts to enforce its patent rights against competitors in its specialized therapeutic areas. Ipsen has a history of strategic acquisitions, such as Clementia Pharmaceuticals in 2019 for rare bone diseases and Epizyme in 2022 for oncology, further bolstering its therapeutic pipeline.